At last some focus. CYP's trialling and ability to find funding research partners and grants good, but they need to start making some inroads and noise therein for the capital mkts:
I am amazed no-one sniffing around given completion of the knee OA enrolment. CYP is at very cheap levels for the first enrolled and largest phase III trial in IPSC's. Excellent partnership negotiation levels for some potential partner with 10-20 million or so shares thrown in for a upfront and milestone cash payment at bargain basement levels.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 16.0¢ | $1.021K | 6.379K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 77738 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 3400 | 1 |
View Market Depth
| Last trade - 09.59am 24/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |